Navigating the highs and lows of psychedelic therapies

Regulators face new challenges over whether — and how — to allow people to receive mind-altering drugs to treat mental health conditions.

Related Keywords

Portugal ,Jamaica ,United States ,Netherlands ,Spain ,London ,City Of ,United Kingdom ,America ,Dutch ,Cole Burston ,Brent Lewin Getty ,James Rucker ,Myles Katz ,George Goldsmith ,Michael Pollan ,Kirk Rutter ,Synthesis Institute ,Researchers At Kings College London ,Netflix ,South America ,Kings College London ,Wild West ,Chemicals ,Clinical Trials ,Data ,Doctors ,Drug And Device Safety ,England ,Governance ,Health Systems ,History ,Industry ,Major And Chronic Diseases ,Medicines ,Mental Health ,Patients ,Pharma ,Policy ,Psychedelics ,Regulation ,Regulatory ,Research ,Research And Development ,Rights ,Risk And Compliance ,Safety ,Society And Culture ,The Netherlands ,Transparency ,